Aspects herein are directed to an anchorable brachytherapy device configured to be permanently implanted in a tumor bed at the time of operative removal of the tumor. In exemplary aspects, the brachytherapy device may comprise a plurality of hollow tubes that form a spherical or ellipsoid shape. Protrusions or grooves may be formed on an outer surface of the tubes to help anchor the brachytherapy device in the tumor bed. Radioactive seeds or strands may be positioned within the tube channels to provide radiation to the tumor bed.

Disclosed is an apparatus for measuring the distribution of radiation dose emitted from a brachytherapy insertion tool, the apparatus including a housing having defined therein a measurement space in which the brachytherapy insertion tool is located, a fluorescent member disposed at the housing, the fluorescent member being configured to react with radiation emitted to the measurement space and to emit light, a camera disposed in the housing, and a cover coupled to one surface of the housing, the cover being configured to cover the fluorescent member. The portion of the fluorescent member to which radiation from a radiation source of the brachytherapy insertion tool is applied reacts with the radiation and generates light, brightness of the light varies depending on distribution of the radiation, and the position at which the light is bright is calculated to measure the direction in which the brachytherapy insertion tool has no shielding.

A template assembly including a first grid (22) for placement on a first side of a body organ, defining a plurality of apertures (329) adapted to receive elongate applicators (410), a second grid (24) for placement on a second side of a body organ, defining a plurality of apertures (34), adapted to receive applicators passing through apertures of the first grid and the body organ and at least one frame (26) defining a large hole (72), positioned between the first and second grids and configured to grasp the body organ.

A device for treating a tumor, including a needle for insertion into the tumor, a solution generator configured to generate a liquid solution including free radionuclides at a concentration of at least 1*10.sup.6 atoms per microliter, and a pump which continuously pumps the generated solution into the needle.

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

A delivery system and method for radiation shielded brachytherapy has a drive assembly, and a plurality of shield assemblies, pivotally mounted to the drive assembly, each having a tubular body defining an outer surface and a bore longitudinally extending between opposite ends of the tubular body. Each of the shield assemblies has radiation shielding material extending about a circumferential portion of the tubular body and disposed between the outer surface and the cavity. An interlocking system is operatively mounted to the rotating assembly, and engages a group of the plurality of shield assemblies. The interlocking system is configured for transmitting a rotational input received from a driving mechanism to the group of shield assemblies, for synchronously rotating each shield assembly of the group about their respective longitudinal axis.

Systems, kits and methods for preparing an injection system and/or treating target lesions with a selective internal radiation therapy which includes a double-barrel syringe loaded with a two-component tissue glue and radioisotope loaded microspheres. The microspheres are loaded into the syringe based on the size of the target location and are administered with a needle or dual-lumen catheter. Dosing regimens for treating breast cancer lesions or surgical beds up to 130 mm in diameter and hepatocellular carcinoma lesions up to 50 mm are included.

Disclosed herein are methods of treating a patient in need of therapy for prostate cancer comprising delivering a β-radiation-emitting composition into the prostatic vasculature. In some embodiments, an absorbed dose of 60 Gy to 200 Gy is delivered to the prostate. In some embodiments, the β-radiation-emitting composition is delivered into the arterial vasculature of the prostate via a catheter. In some embodiments, the β-radiation-emitting composition comprises a suspension of the β-radiation-emitting particles in an aqueous liquid.

An apparatus and methods for embolization of a patient includes vials for containing radiomicrospheres including inclined and domed base are described. Apparatus for delivering the microspheres from the vials to a patient for radioembolization are also described.

According to some aspects, a carrier configured for use with a broadband x-ray source comprising an electron source and a primary target arranged to receive electrons from the electron source to produce broadband x-ray radiation in response to electrons impinging on the primary target is provided. The carrier comprising a housing configured to be removeably coupled to the broadband x-ray source and configured to accommodate a secondary target capable of producing monochromatic x-ray radiation in response to incident broadband x-ray radiation, the housing comprising a transmissive portion configured to allow broadband x-ray radiation to be transmitted to the secondary target when present, and a blocking portion configured to absorb broadband x-ray radiation.